Skip to content

Xencor XNCR Cash ratio

Cash ratio at other companies

Amgen logo
AmgenAMGN
0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.6×-0.3×
Janux Therapeutics logo
Janux TherapeuticsJANX
0.9×-3.3×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
2.2×-0.3×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
+3.7×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
13.7×+10.1×

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+76.3%
Enterprise value$1.23B+55.9%
P/S11×+6.2×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on the most recent quarter.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's cash ratio?
Xencor (XNCR) reported cash ratio of 0.2× in Q1 2026.
How has Xencor's cash ratio changed year-over-year?
Xencor's cash ratio decreased by 57.0% year-over-year, from 0.4× to 0.2×.
What is the long-term trend for Xencor's cash ratio?
Over 5 years (2020 to 2025), Xencor's cash ratio has grown at a -16.0% compound annual growth rate (CAGR), from 1.4× to 0.6×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.